

Appendix: the opportunity of point-of-care diagnostics in general practice: modelling the effects on antimicrobial resistance

Contents

1	Supplemental methods	1
1.1	Demographic module	2
1.2	Consultation module	3
1.3	AMR module	4
1.4	R environment and packages	13
2	Supplemental results	15
2.1	Supplemental figures	15
2.2	Supplemental tables	15

1 Supplemental methods

MERIAM (Modelling the Economics of Respiratory tract Infections and AMr) is a model built to assess the long-term health-economic effects of improved diagnostics for community-acquired acute respiratory tract infections at the first point of care. The model is developed within the VALUE-Dx project.

MERIAM has three modules: the demographic module, used to model the population over a long time horizon; the consultation module, used to model patients going to care with an acute respiratory tract infection and the antimicrobial resistance (AMR) forecasting module, used to forecast AMR levels.

The demographic module contains a representative sample of the modeled country. The consultation model uses incidence data to simulate the care-seeking behaviour for community-acquired respiratory tract infections of a subset of individuals from the demographic model and their outcomes, including diagnostics, costs and antibiotic consumption. The AMR module uses antibiotic consumption data to forecast AMR levels.

The time framework of this model is as follows:

- Individuals may seek care for respiratory complaints, with associated costs and health outcomes (in this case mainly prescriptions of antibiotics). The incidence depends on the time of the year (e.g. there will be an annual peak in the Winter).
- Annually, assess the impact of AMR, based on the consumption of antibiotics.
- Annually, demographic changes (mortality, births, migration) is applied.
- Repeat for 10 years.

Table 1: example of ten individuals in the model

id	active	sex	age
12040402442	1	0	12
6180361747	1	1	6
52072970845	1	0	52
5072433547	1	0	5
15007965808	1	0	15
81156617227	1	1	81
33028319974	1	0	33
28114886520	1	1	28
32086984159	1	0	32
94092723188	1	0	94

1.1 Demographic module

Within the model, nodes are created to represent individuals. Populations are based on demographic data from Eurostat, mainly incorporating age and sex, and can be made as large as needed. The ID number is an unique identifier of each node; active indicated whether an individual is alive, sex is 0 for male and 1 for female, age is age (0-99).

The population changes over time are made visible using population pyramids, which are included here. See an example with 10 individuals below in table 1.

1.1.1 Annual demographic changes

Every year the population is updated to reflect the Eurostat projections, here we use model cycles of one year. The following is included:

- Mortality
- Ageing
- Fertility
- Migration

This effectively means we assume everyone is born and dies on January 1.

1.1.1.1 Mortality Mortality is based on the Eurostat mortality probability projections. The mortality probability is sampled for the active nodes of all age groups. A major assumption in the model is that all nodes over 99 are excluded: we do not include centenarians in the model. This is mainly due to data availability for this group.

1.1.1.2 Ageing Ageing is straightforward in that it increases the age with 1 annually.

1.1.1.3 Fertility Data on births are used from the Eurostat population projections. The number of babies born is related to the population aged 15-45. The births() function takes the node_list as an input and returns the node_list with newly-created nodes (babies). See an example here:

Table 2: Overview data sources

Data	Used for	ID
Population projections	Population, sex, age, fertility	proj_19np
Migration rates	Migration	proj_19nanmig
Mortality rates	Mortality	proj_19naasmr

1.1.1.4 Migration The model accounts for migration by using the Eurostat projections. The Eurostat projections provide total numbers of immigration (positive number) and emigration (negative number) for 2019-2100. In MERIAM this is related to the total population and converted to a rate. This rate is then used to calculate the total number of immigrants and emigrants. This basically assumes that both immigration and emigration increase when the population size increases.

1.1.1.5 Overview data sources For countries within the European Union, the Eurostat [8] data sources used are displayed in table 2. For the United Kingdom, the population projection data from the Office for National Statistics are used.

1.2 Consultation module

Each week, a subset of nodes will seek care. These nodes are selected based on real-world incidence data.

1.2.1 Incidence

Incidence is modeled using the Incidence package. Data is from ECDC. Both Acute Respiratory Infection (ARI) and Influenza-Like Illness (ILI) are modeled (if data is available). Incidence data is stratified by the following age groups:

- 0-4 years
- 5-14 years
- 15-64 years
- 65 years and over

Incidence data is read into R and then converted into an incidence object from the Incidence package. Two exponential models will be created for each year, one where the number of cases increases over time and one where the number cases decrease. This way, an annual peak is created in the influenza season. The function `fit_optim_split()` from the incidence package is used to automatically determine the peak of the influenza season.

At the start of each model run, the exact incidence is calculated using the model for all weeks. See an example in table 3 for 4 weeks in a model run with 10,000 nodes for the Netherlands.

1.2.2 Index consultation

During the index consultation, a clinician will perform tests, prescribe antibiotics etc. on the individuals seeking care. For all nodes seeking care (as described above), tests and antibiotic prescriptions are sampled.

As far as the tests are not part of the intervention (in the CRP testing scenario, everyone received a CRP test), they are sampled using the PPAS data [22].

Antibiotics are also sampled using the PPAS data: the proportion of antibiotic prescriptions is stratified by age (two categories: younger than 60 and 60 and older).

Table 3: Example of incidence in model (per 10,000 inhabitants), for Influenza-like illness (ILI) and Acute respiratory-tract infection (ARI), per week

Week	ILI	ARI
2020-01	42	245
2020-02	40	250
2020-03	38	241
2020-04	36	233

Table 4: Probabilities related to diagnostics and antibiotics for the Netherlands

Probability	Value	Distribution
Antibiotic prescription (age: 60 and older)	0.47 [58 - 66]	Beta [alpha - beta]
Antibiotic prescription (age: younger than 60)	0.28 [54 - 141]	Beta [alpha - beta]
Prescription of amoxicillin	0.68 [76 - 36]	Beta [alpha - beta]
Prescription of flucloxacillin	0.05 [6 - 106]	Beta [alpha - beta]
Prescription of amoxiclav	0.06 [7 - 105]	Beta [alpha - beta]
Prescription of doxycycline	0.21 [23 - 89]	Beta [alpha - beta]
Prescription of azithromycin	0.04 [4 - 108]	Beta [alpha - beta]
Prescription of levofloxacin	0.01 [1 - 111]	Beta [alpha - beta]
Diagnostic: CRP	0.32 [99 - 213]	Beta [alpha - beta]

1.2.3 Overview data sources

1.2.3.1 Probabilities In table 4, the probabilities related to diagnostics and antibiotics are displayed. These data are from the PPAS [22].

1.2.3.2 Costs For general practitioner (GP) consults, the Dutch costing manual was used [13], while for pharmaceuticals, including the delivery costs, Dutch list prices are used [24]. An overview can be found in table 5

1.3 AMR module

The AMR model uses a two-step approach. First, the baseline AMR projections are generated, using an ensemble model. This is a data-driven approach where current trends are used to forecast future AMR rates. These baseline projections are then used as for the current-care scenario, where we assume current patterns in AMR will continue in the future. The second step is to incorporate the impact on antibiotic consumption from the diagnostic strategies, in the baseline AMR projections. This uses a more mechanistically-driven approach. The steps are described in more details below.

Within the VALUE-Dx project, we aim to assess the long-term effects of rapid diagnostics on antimicrobial resistance (AMR). The first step in this process is to forecast AMR rates when the status quo is preserved, i.e. current AMR policies remain, but no additional measures are taken. Predicting antimicrobial resistance (AMR) is a challenging task, as the development and subsequent spread of resistance genes is highly uncertain. Two methods of modelling AMR in the population over time have been identified [20]:

- Mechanistic dynamic transmission models, which models the transmission of resistant pathogens through populations, requiring information on the mechanisms of spread of resistant pathogens.
- Statistical forecasting methods, which is a data-driven approach where the underlying mechanisms of resistance is not considered: past trends are used to forecast future AMR rates.

Table 5: Consult costs used in the model

groupname	Item	nl	Reference
Consults (costs per consult)	GP consult	€35.37	Costing manual
	pharmacy fee	€13	List prices pharmaceuticals
	amoxicillin	€5.56	List prices pharmaceuticals
Antibiotic types (costs per course)	flucloxacillin	€4.76	List prices pharmaceuticals
	amoxiclav	€7.72	List prices pharmaceuticals
	doxycycline	€3.15	List prices pharmaceuticals
	azithromycin	€1.95	List prices pharmaceuticals
	levofloxacin	€6.80	List prices pharmaceuticals
Diagnostics	crp	€4.36	Costing manual

Additionally, expert elicitation is a viable method to forecast AMR, which can be combined with these modeling approaches [5]. The mechanisms to attain and retain resistance may differ between various pathogens. As we aim to assess the impact of diagnostics for all community-acquired respiratory-tract infections in the population, which can be caused by various pathogens [17], we considered a mechanistic dynamic transmission model not to be a viable strategy. A statistical forecasting method, comparable to the methods used by Hashiguchi et al. was used for this study [14].

Several methods are available for time series forecasting [16, 11], but selecting a single ‘best’ model is challenging. Ensemble methods are an often-used technique to improve forecasts: instead of picking one model, several models are used simultaneously and then combined to provide an average. We developed an ensemble model, averaging three models:

- An exponential smoothing (ETS) model, which forecasts future data using weighted averages of past observations. [16]
- A random forest, which aggregates many regression trees to estimate the outcome of interest (AMR rates in our case) [1]. Bagging (bootstrapping and aggregating) is used, where each decision tree is informed by a random sample, with only a subset of the available regressors, of the original data set. The different trees are grown in parallel, i.e. new trees are not informed by previous trees.
- An XGBoost model, which also combines many regression trees to estimate the outcome of interest, however, as opposed to random forests, a sequential tree growing algorithm (boosting) is used, where each new tree informs the creation of the next tree [4].

1.3.1 Missing data

The European consumption and AMR data had some missing data. These were imputed using the Amelia algorithm [15] which allows for time-series-cross-sectional data to be imputed. To incorporate uncertainty in the various forecasts, the imputation algorithm was run 2000 times to incorporate uncertainty.

1.3.2 Forecasts of antibiotic consumption

Antibiotic consumption of broad-spectrum penicillins was forecast using an ETS model.

There are different ETS methods. As we considered annual data, we did not consider seasonal components. The trend can be either none, additive, additive damped or multiplicative. Multiplicative trends tend to

produce poor forecasts and additive trends can overestimate the trend on the long term [16], hence we considered an additive damped trend. The consumption data were box-cox transformed so that the data resembled a normal distribution. An example is displayed in figure 1.




Figure 1: Antibiotic consumption forecast

1.3.3 AMR forecasts

For the antimicrobial resistance forecasts the dataset was split into a training and a testing set (training: 2005-2014, testing: 2015-2018), to be able to measure the performance of the forecasts. After fitting the different models to the training set, the prediction of the testing set was assessed. Then the models were refit to the full dataset to forecast the AMR rates up to 2050.

Although we only assessed resistance of *Streptococcus pneumoniae* to broad-spectrum penicillins in the Netherlands in this paper, we incorporated data from other bug-drug combinations and European countries as regressors in the random forest and XGBoost models.

1.3.3.1 Exponential smoothing model The exponential smoothing model uses a similar approach as described for the consumption forecasts, hence an additive, damped, trend.

1.3.3.2 Random forest model The random forest model uses the following regressors to predict the AMR rate:

- Antibiotic consumption
- GDP forecasts (corrected for purchasing power parities)
- Forecasts proportion population aged < 15 years
- Forecasts proportion population aged > 64 years
- Forecasts healthcare expenditure (% of GDP)
- Forecasts out-of-pocket spending on health (% of total spending on health)

The ranger R package was used to build the model [23]. The model was tuned to minimize the root mean square error (RMSE), which resulted in a mtry (number of variables included in each bootstrapped sample of 25 and a min.node.size (minimum number of observations in terminal nodes) of 3 [19].

1.3.3.3 XGBoost model The XGBoost [4] model uses the same dependent variables as the random forest model. After tuning the following hyperparameters were chosen:

- min_child_weight: 3 (minimum number of instances in child node)
- max_depth: 11 (maximum depth of each tree)
- eta 0.00920 (learning rate)
- gamma: 0.00158 (mimumum loss reduction to make a further partition on a lead node of the tree)

Below are the feature importance plot, an example of a tree used in the XGBoost model and an example of a forecast:

1.3.3.4 Accuracy of predictions The accuracy of the different models is calculated on the testing set, using the models trained only on the training set. Figure 2 shows an example of the calibration of one model iteration.

The performance of time-series forecasts are often represented using the root mean squared error (RMSE), which is calculated using the following formula [16]:

$$RMSE = \sqrt{\text{mean}(e_t^2)}$$

Where e_t is the forecast error of values from the testing set.

The values differ within the probabilistic analysis, table 6 gives an overview:

Table 6: Overview accuracy metrics AMR predictions

.model_desc	mae	mape	mase	rmse	rsq	smape
RANGER	0.07 [0.04 - 0.11]	2.8 [1.67 - 4.3]	0.68 [0.41 - 1.03]	0.08 [0.05 - 0.12]	0.6 [0.01 - 0.97]	2.77 [1.66 - 4.23]
XGBOOST	0.06 [0.03 - 0.11]	2.34 [1.06 - 4.41]	0.58 [0.26 - 1.08]	0.07 [0.03 - 0.12]	0.88 [0.66 - 0.98]	2.32 [1.06 - 4.41]
ETS	0.14 [0.12 - 0.17]	5.57 [4.91 - 6.51]	1.34 [1.17 - 1.52]	0.16 [0.15 - 0.19]	0.76 [0.76 - 0.78]	5.36 [4.74 - 6.23]

Note:

mae: mean absolute error; mape: mean absolute percentage error; mase: mean absolute scaled error; root mean square error; rsq: r-squared; smape: symmetric mean absolute percentage error

1.3.3.5 Forecasts of individual models Figure 3 gives the AMR forecasts of the individual models.

1.3.3.6 Ensemble The ensemble model is created by averaging (with equal weights) the predicted values across the models. An example is provided in figure 4.




Figure 2: AMR forecast calibration



Figure 3: Antimicrobial resistance forecasts




Figure 4: Ensemble model forecasts

1.3.3.7 Incorporating uncertainty The previously described forecasting methods generate point forecasts, that is, a mean is forecast, but no statistical distribution. To incorporate uncertainty in the AMR forecasting model, the following input parameters are varied and the models are fitted for 2000 iterations:

- A different imputed data set is used for both the historical AMR data and antibiotic consumption
- Forecasts healthcare expenditure (% of GDP) are varied for the model replications
- Forecasts out-of-pocket spending on health (% of total spending on health) are varied for the model replications

Consequently, all model replications use slightly different AMR projections. However, we have not quantified all uncertainty associated with the projections, i.e. not all possible future AMR rates are included in the modeling.

1.3.4 Incremental effects of diagnostic strategies

As has been described elsewhere, there is a clear relationship between antibiotic consumption and national AMR rates[12, 2]. We use this relationship to relate the change in antibiotic consumption, as estimated in MERIAM, to future AMR levels (projected as described above). The following formula is used:

$$p_{Test,t}^{Ab,B} = p_{Base,t}^{Ab,B} \times \frac{C_{Test,t-1}^{Ab}}{C_{Base,t-1}^{Ab}} \times \epsilon^{Ab,B}$$

Where $p_{Test,t}^{Ab,B}$ is the proportion of resistance of bacterium B to antibiotic Ab under the testing scenario in the year t ; $p_{Base,t}^{Ab,B}$ the proportion of resistance of bacterium B to antibiotic Ab under the base case scenario in the year t ; $C_{Test,t-1}^{Ab}$ the antibiotic consumption of antibiotic Ab in the year $t - 1$ in the testing scenario; $C_{Base,t-1}^{Ab}$ the antibiotic consumption of antibiotic Ab in the year $t - 1$ in the base case scenario and ϵ the elasticity between antibiotic consumption of antibiotic Ab and the development of resistance in bacterium B .

1.3.4.1 Estimating elasticity The elasticity ϵ is given by the following formula:

$$\epsilon = \frac{\% \text{ change in resistance}}{\% \text{ change in consumption}}$$

We calculate the elasticity from the historical antibiotic consumption and resistance data from the ECDC across all countries included in the dataset [7]. Using ordinary least squares regression on the historical (non-missing) data, a linear function is estimated. See below for the example of the proportion of resistant pneumococci and the consumption of broad-spectrum penicillins:

This function is then used to estimate the elasticity using the midpoint method, which uses the average percent change of both resistance proportions (p) and antibiotic consumption (C) between two points on the linear function:

$$\epsilon = \frac{\frac{p_2 - p_1}{(p_2 + p_1)/2} \times 100}{\frac{C_2 - C_1}{(C_2 + C_1)/2} \times 100}$$

The elasticity is not constant, it varies based on the location on the line. To give two examples, a drop from 3 ddd to 2 ddd (daily per 1000 population), a 33% drop, corresponds to an elasticity of 0.72, resulting in a decline of AMR levels by 24%. However, a drop from 9 ddd to 6 ddd (also a 33% drop), corresponds to an




Figure 5: Historical consumption of broad spectrum penicillins and resistance of pneumococci

elasticity of 0.89, causing an AMR rate decline of 29%. This also matches prior beliefs, as we would expect a larger influence of antibiotic consumption reductions in countries with a high consumption, compared to countries with a lower consumption. Although antibiotic consumption is the only parameter used here to estimate AMR levels, in reality this is not the only parameter. This is also clear from the graph above, the R^2 is 0.28, so the correlation is by no means perfect.

1.3.5 Overview data sources

The input data were used based on literature [14] and expert opinion, see table 7 for an overview.

Table 7: Overview data sources AMR model

Data	Database	Notes	Reference
Antimicrobial resistance	Surveillance Atlas for Infectious Disease		[7]
Antibiotic consumption	ECAC-Net		[6]
Population projections	Eurostat		[10]
Historical demographic data			[9]
GDP projections	OECD	Used for OECD countries	[18]
GDP per capita	World Bank	Used for non-OECD countries	[21]
Health expenditure projections	Literature		[3]
Out-of-pocket healthcare payments projections	Literature		[3]

1.4 R environment and packages

The current R version in use for MERIAM is R version 4.1.0 (2021-05-18). The Checkpoint package is used to be able to use packages in a reproducible manner, this forces all packages to use the version as published on CRAN on 20 July, 2021.

An overview of the included packages is displayed in table 8.

Table 8: Used packages

Package	Version	Authors
Amelia	1.8.0	James Honaker, Gary King, Matthew Blackwell
AMR	1.7.1	M S Berends, C F Luz, A W Friedrich, B N M Sinha, C J Albers, C Glasner
checkpoint	1.0.0	Hong Ooi, Andrie de Vries, Microsoft
compiler	4.1.0	R Core Team
countrycode	1.3.0	Vincent Arel-Bundock, Nils Enevoldsen, CJ Yetman
dials	0.0.9	Max Kuhn
doFuture	0.12.0	Henrik Bengtsson
doRNG	1.8.2	Renaud Gaujoux
dplyr	1.0.7	Hadley Wickham, Romain François, Lionel Henry, Kirill Müller
forcats	0.5.1	Hadley Wickham
furrr	0.2.3	Davis Vaughan, Matt Dancho
ggplot2	3.3.5	Hadley Wickham
incidence	1.7.3	Zhian , N. , Kamvar , Jun , Cai , Juliet , R.C. , Pulliam , Jakob , Schumacher, Thibaut , Jombart , Thibaut , Jombart , Zhian , N. , Kamvar , Rich , FitzJohn , Jun , Cai , Sange
lubridate	1.7.10	Garrett Grolemund, Hadley Wickham
magrittr	2.0.1	Stefan Milton Bache, Hadley Wickham
modeltime	0.7.0	Matt Dancho
purrr	0.3.4	Lionel Henry, Hadley Wickham
readr	1.4.0	Hadley Wickham, Jim Hester
readxl	1.3.1	Hadley Wickham, Jennifer Bryan
stringr	1.4.0	Hadley Wickham
tibble	3.1.2	Kirill Müller, Hadley Wickham
tidymodels	0.1.3	Max Kuhn, Hadley Wickham
tidyr	1.1.3	Hadley Wickham
timetk	2.6.1	Matt Dancho, Davis Vaughan
truncnorm	1.0.8	Olaf Mersmann, Heike Trautmann, Detlef Steuer, Björn Bornkamp
yaml	2.2.1	Jeremy Stephens, Kirill Simonov, Yihui Xie, Zhuoer Dong, Hadley Wickham, Jeffrey Horner, reikoch, Will Beasley, Brendan O'Connor, Gregory R. Warnes
gt	0.3.0	Richard Iannone, Joe Cheng, Barret Schloerke
kableExtra	1.3.4	Hao Zhu
knitr	1.33	Yihui , Xie , aut , cre , < https://orcid.org/0000-0003-0645-5666 >, Yihui, Xie , Yihui, Xie
patchwork	1.1.1	Thomas Lin Pedersen
reactable	0.2.3	Greg Lin
rmarkdown	2.10	JJ , Allaire , Yihui , Xie , Jonathan , McPherson, Javier , Luraschi , Kevin , Ushey , Aron , Atkins , Hadley , Wickham , Joe , Cheng , Winston , Chang , Richard , Iannone , Yil
scales	1.1.1	Hadley Wickham, Dana Seidel

2 Supplemental results

2.1 Supplemental figures

Figure 6 details the demographic development of the population. The example is from one model replication for illustration purposes, there may be small differences between the various model runs. Figure 7 displays the incidence of respiratory tract infections in the modelled years.

2.2 Supplemental tables

Table 9 displays the same costs as Table 1 of the main paper, however, the costs are not discounted. In table 10 are all costs (not discounted), grouped by year, shown are the median and the 95% credible intervals. Displayed in table 11 is the median annual antibiotic consumption in defined daily dosages, including the 95% credible intervals, for the different classes of antibiotics.

```
## 'summarise()' has grouped output by 'country', 'name'. You can override using the '.groups' argument
```

```
## 'summarise()' has grouped output by 'country'. You can override using the '.groups' argument.
```

Table 9: Undiscounted costs

Cost type	Current standard-of-care	Incremental costs conservative scenario	Incremental costs uncertain scenario
consults	€6,079,643 (€5,464,075 - €6,800,547)	€0 (-€248 - €248)	€0 (-€248 - €248)
antibiotics	€1,031,870 (€853,496 - €1,231,761)	-€196,510 (-€393,191 - €9,879)	-€197,375 (-€389,453 - €14,205)
diagnostics	€236,757 (€195,815 - €285,837)	€1,550,974 (€1,387,462 - €1,739,797)	€775,928 (€684,646 - €881,291)
training	€0 (€0 - €0)	€97,557 (€97,488 - €97,625)	€97,557 (€97,487 - €97,624)
total	€7,345,854 (€6,599,496 - €8,212,296)	€1,452,499 (€1,206,421 - €1,722,893)	€674,503 (€472,297 - €915,668)




Figure 6: Demographic projections




Figure 7: Incidence projections

Table 10: Total costs

Cost category	Year	Current standard-of-care	Incremental costs conservative scenario	Incremental costs uncertain scenario
Netherlands				
antibiotics	2020	€98,927 [€80,748 - €121,655)	-€6,970 [-€14,309 - €452)	-€7,037 [-€14,180 - €577)
	2021	€100,085 [€81,806 - €121,925)	-€14,078 [-€28,685 - €801)	-€14,197 [-€28,568 - €1,328)
	2022	€100,946 [€82,426 - €122,625)	-€21,309 [-€42,891 - €1,267)	-€21,584 [-€42,683 - €1,776)
	2023	€101,740 [€83,423 - €124,198)	-€21,391 [-€43,341 - €1,225)	-€21,652 [-€43,498 - €1,771)
	2024	€102,598 [€83,511 - €124,812)	-€21,604 [-€43,501 - €965)	-€21,826 [-€43,291 - €1,735)
	2025	€103,779 [€85,151 - €126,518)	-€21,806 [-€44,372 - €1,068)	-€22,020 [-€43,983 - €1,686)
	2026	€104,483 [€85,915 - €128,356)	-€22,128 [-€44,151 - €1,136)	-€22,167 [-€43,549 - €1,477)
	2027	€105,302 [€86,371 - €127,343)	-€22,279 [-€44,574 - €1,313)	-€22,407 [-€44,522 - €1,394)
	2028	€106,292 [€87,245 - €128,584)	-€22,343 [-€44,654 - €1,021)	-€22,594 [-€44,502 - €1,565)
	2029	€107,190 [€88,346 - €130,770)	-€22,577 [-€45,641 - €1,207)	-€22,763 [-€45,222 - €1,695)
consults	2020	€589,836 [€523,098 - €677,554)	€0 [€0 - €0)	€0 [€0 - €0)
	2021	€594,327 [€526,071 - €682,186)	€0 [€0 - €0)	€0 [€0 - €0)
	2022	€597,545 [€532,024 - €680,660)	€0 [-€70.73 - €70.73)	€0 [-€70.73 - €70.73)
	2023	€600,445 [€533,424 - €688,881)	€0 [-€70.73 - €70.73)	€0 [-€70.73 - €70.73)
	2024	€604,636 [€536,219 - €687,741)	€0 [-€70.73 - €70.73)	€0 [-€70.73 - €70.73)
	2025	€608,031 [€539,366 - €694,777)	€0 [-€70.73 - €70.73)	€0 [-€70.73 - €70.73)
	2026	€610,242 [€546,297 - €711,726)	€0 [-€70.73 - €70.73)	€0 [-€70.73 - €70.73)
	2027	€615,211 [€548,700 - €705,861)	€0 [-€35.37 - €35.37)	€0 [-€35.37 - €35.37)
	2028	€617,987 [€548,700 - €705,491)	€0 [-€35.37 - €35.37)	€0 [-€35.37 - €35.37)
	2029	€622,107 [€553,037 - €711,327)	€0 [-€35.37 - €35.37)	€0 [-€35.37 - €35.37)
diagnostics	2020	€23,017 [€18,821 - €28,431)	€55,762 [€49,064 - €64,111)	€27,861 [€24,205 - €32,437)
	2021	€23,129 [€18,947 - €28,710)	€112,351 [€99,170 - €129,228)	€56,196 [€48,689 - €65,231)
	2022	€23,336 [€19,126 - €28,427)	€168,888 [€149,326 - €194,352)	€84,487 [€73,912 - €97,618)
	2023	€23,412 [€18,987 - €28,758)	€169,828 [€150,441 - €195,466)	€84,839 [€74,115 - €98,778)
	2024	€23,578 [€19,244 - €29,050)	€171,038 [€151,430 - €195,176)	€85,529 [€74,784 - €98,473)
	2025	€23,776 [€19,423 - €29,235)	€172,132 [€152,445 - €198,415)	€86,038 [€75,054 - €99,662)
	2026	€23,807 [€19,645 - €29,303)	€172,619 [€154,322 - €201,320)	€86,298 [€75,544 - €101,611)
	2027	€23,997 [€19,606 - €29,461)	€173,965 [€153,753 - €200,665)	€86,912 [€75,855 - €100,968)
	2028	€24,145 [€19,693 - €29,617)	€174,836 [€154,598 - €200,623)	€87,614 [€76,582 - €101,425)
	2029	€24,245 [€19,846 - €29,853)	€175,895 [€155,536 - €202,182)	€88,005 [€76,484 - €102,273)
total	2020	€711,678 [€631,498 - €819,865)	€58,398 [€49,379 - €68,937)	€30,340 [€22,838 - €39,347)

Table 10: Total costs (*continued*)

Country	Cost category	Year	Current standard-of-care	Incremental costs conservative scenario	Incremental costs uncertain scenario
		2021	€717,041 [€634,380 - €823,261]	€107,779 [€90,061 - €129,608]	€51,522 [€36,725 - €69,734]
		2022	€721,508 [€640,555 - €821,419]	€157,349 [€130,483 - €188,973]	€72,579 [€50,307 - €99,636]
		2023	€725,564 [€642,850 - €834,457]	€158,249 [€130,787 - €191,273]	€72,902 [€50,204 - €100,899]
		2024	€730,940 [€645,972 - €835,152]	€159,372 [€130,160 - €191,711]	€73,406 [€51,317 - €99,725]
		2025	€735,248 [€653,697 - €844,661]	€160,265 [€131,562 - €194,592]	€73,916 [€50,665 - €100,545]
		2026	€738,955 [€658,911 - €857,975]	€161,196 [€132,345 - €195,215]	€74,095 [€51,029 - €103,027]
		2027	€745,136 [€662,878 - €853,358]	€162,220 [€133,305 - €195,070]	€74,656 [€51,579 - €101,957]
		2028	€748,365 [€663,752 - €854,892]	€162,580 [€133,793 - €196,170]	€75,042 [€51,610 - €102,998]
		2029	€753,571 [€667,230 - €860,840]	€163,542 [€134,015 - €195,865]	€75,183 [€51,670 - €103,786]
	training	2020	€0 [€0 - €0]	€9,566 [€9,566 - €9,566]	€9,566 [€9,566 - €9,566]
		2021	€0 [€0 - €0]	€9,617 [€9,615 - €9,619]	€9,617 [€9,615 - €9,619]
		2022	€0 [€0 - €0]	€9,666 [€9,663 - €9,670]	€9,666 [€9,663 - €9,670]
		2023	€0 [€0 - €0]	€9,709 [€9,704 - €9,714]	€9,709 [€9,704 - €9,714]
		2024	€0 [€0 - €0]	€9,748 [€9,742 - €9,754]	€9,748 [€9,742 - €9,754]
		2025	€0 [€0 - €0]	€9,784 [€9,776 - €9,792]	€9,784 [€9,776 - €9,792]
		2026	€0 [€0 - €0]	€9,819 [€9,809 - €9,828]	€9,819 [€9,810 - €9,828]
		2027	€0 [€0 - €0]	€9,852 [€9,841 - €9,862]	€9,852 [€9,841 - €9,862]
		2028	€0 [€0 - €0]	€9,883 [€9,871 - €9,895]	€9,883 [€9,871 - €9,895]
		2029	€0 [€0 - €0]	€9,913 [€9,900 - €9,926]	€9,913 [€9,900 - €9,926]

Table 11: Annual antibiotic consumption

Antibiotic class	Year	Current standard-of-care	Conservative scenario	Uncertain scenario
Netherlands				
Amoxicillin/clavulanic acid	2020	3297 (1396 - 6174)	3108 (1670 - 5187)	3118 (1669 - 5260)
	2021	3350 (1449 - 6332)	2898 (1606 - 4725)	2888 (1596 - 4882)
	2022	3350 (1375 - 6353)	2662 (1091 - 5072)	2646 (1186 - 5145)
	2023	3370 (1438 - 6374)	2656 (1102 - 5114)	2656 (1176 - 5271)
	2024	3412 (1428 - 6594)	2698 (1112 - 5124)	2678 (1155 - 5334)
	2025	3454 (1480 - 6636)	2740 (1134 - 5229)	2709 (1176 - 5344)
	2026	3486 (1448 - 6678)	2730 (1124 - 5250)	2751 (1208 - 5419)
	2027	3518 (1501 - 6720)	2762 (1102 - 5367)	2782 (1218 - 5366)
	2028	3560 (1460 - 6552)	2788 (1124 - 5272)	2793 (1228 - 5502)
	2029	3580 (1522 - 6815)	2835 (1144 - 5292)	2824 (1239 - 5492)
Broad-spectrum penicillins	2020	37406 (29894 - 46778)	34786 (28728 - 42433)	34766 (28811 - 42842)
	2021	37674 (30208 - 47484)	32424 (26438 - 39932)	32487 (26533 - 40173)
	2022	38084 (30260 - 47859)	30104 (22994 - 38946)	30046 (23476 - 39407)
	2023	38398 (30491 - 48196)	30408 (23089 - 39470)	30324 (23551 - 39376)
	2024	38756 (30990 - 48575)	30660 (23329 - 39419)	30644 (23708 - 39820)
	2025	39070 (31195 - 48837)	30912 (23488 - 39902)	30812 (23886 - 40113)
	2026	39501 (31499 - 49162)	31174 (23654 - 40059)	31180 (24212 - 40826)
	2027	39806 (31626 - 49529)	31490 (23772 - 40868)	31426 (24475 - 40951)
	2028	39989 (32056 - 49729)	31794 (24233 - 40961)	31647 (24664 - 41118)
	2029	40462 (32389 - 50959)	32036 (24191 - 41509)	31804 (24863 - 41638)
Narrow-spectrum penicillins	2020	3752 (1512 - 7561)	3528 (1890 - 6314)	3570 (1778 - 6315)
	2021	3822 (1526 - 7672)	3346 (1736 - 5699)	3304 (1722 - 5810)
	2022	3822 (1498 - 7756)	3038 (1176 - 6328)	2996 (1162 - 5978)
	2023	3843 (1540 - 7770)	3066 (1204 - 6328)	3052 (1134 - 6105)
	2024	3871 (1568 - 7896)	3122 (1204 - 6300)	3080 (1134 - 6146)
	2025	3906 (1582 - 7883)	3136 (1218 - 6357)	3122 (1162 - 6216)
	2026	3983 (1638 - 7981)	3185 (1232 - 6552)	3122 (1106 - 6412)
	2027	3976 (1582 - 7994)	3206 (1190 - 6482)	3150 (1176 - 6300)
	2028	4011 (1624 - 8316)	3192 (1246 - 6608)	3164 (1162 - 6384)
	2029	4046 (1652 - 8303)	3206 (1260 - 6735)	3178 (1204 - 6440)
Macrolides/lincosamides	2020	619 (176 - 1447)	598 (252 - 1184)	590 (248 - 1188)

Table 11: Annual antibiotic consumption (*continued*)

Country	Antibiotic class	Year	Current standard-of-care	Conservative scenario	Uncertain scenario
		2021	630 (173 - 1462)	558 (241 - 1062)	551 (238 - 1069)
		2022	630 (184 - 1476)	497 (155 - 1174)	493 (148 - 1196)
		2023	637 (176 - 1483)	504 (158 - 1217)	490 (140 - 1192)
		2024	644 (191 - 1505)	508 (166 - 1217)	500 (144 - 1217)
		2025	644 (191 - 1501)	518 (158 - 1206)	504 (151 - 1224)
		2026	652 (191 - 1530)	518 (162 - 1199)	504 (144 - 1224)
		2027	666 (198 - 1509)	520 (169 - 1217)	515 (155 - 1246)
		2028	664 (191 - 1530)	529 (162 - 1224)	513 (148 - 1264)
		2029	666 (194 - 1555)	531 (166 - 1242)	522 (151 - 1253)
	Quinolones	2020	158 (10 - 864)	168 (19 - 629)	170 (19 - 662)
		2021	163 (10 - 878)	158 (19 - 534)	168 (19 - 566)
		2022	168 (10 - 874)	120 (5 - 669)	130 (10 - 672)
		2023	163 (10 - 882)	120 (5 - 662)	130 (10 - 682)
		2024	163 (10 - 907)	120 (5 - 654)	134 (5 - 678)
		2025	173 (10 - 883)	125 (5 - 679)	134 (5 - 696)
		2026	168 (10 - 921)	120 (5 - 677)	134 (10 - 720)
		2027	175 (10 - 932)	130 (5 - 696)	134 (5 - 696)
		2028	173 (10 - 923)	125 (8 - 699)	134 (8 - 702)
		2029	178 (10 - 922)	125 (5 - 691)	134 (10 - 716)
	Tetracyclines	2020	7441 (5019 - 10640)	6951 (5061 - 9373)	6937 (5047 - 9451)
		2021	7525 (5026 - 10710)	6528 (4816 - 8701)	6503 (4711 - 8883)
		2022	7602 (5110 - 10710)	6006 (3913 - 8716)	5978 (4039 - 8918)
		2023	7648 (5187 - 10822)	6076 (4011 - 8828)	6072 (3997 - 8940)
		2024	7690 (5292 - 10934)	6132 (4011 - 8800)	6125 (3997 - 9011)
		2025	7784 (5271 - 11054)	6195 (4081 - 9031)	6153 (4074 - 9198)
		2026	7882 (5367 - 11180)	6272 (4130 - 9108)	6216 (4108 - 9353)
		2027	7931 (5389 - 11200)	6314 (4151 - 9199)	6265 (4158 - 9310)
		2028	7994 (5390 - 11340)	6370 (4102 - 9185)	6307 (4130 - 9352)
		2029	8046 (5425 - 11431)	6440 (4220 - 9289)	6363 (4186 - 9471)

References

- [1] Leo Breiman. “Random Forests”. In: *Machine Learning* 45.1 (Oct. 1, 2001), pp. 5–32. ISSN: 1573-0565. DOI: 10.1023/A:1010933404324. URL: <https://doi.org/10.1023/A:1010933404324> (visited on 03/19/2021).
- [2] Michele Cecchini and Sherry Lee. “Low-Value Health Care with High Stakes: Promoting the Rational Use of Antimicrobials”. In: (Jan. 10, 2017), pp. 115–158. DOI: 10.1787/9789264266414-6-en. URL: https://www.oecd-ilibrary.org/social-issues-migration-health/tackling-wasteful-spending-on-health/low-value-health-care-with-high-stakes-promoting-the-rational-use-of-antimicrobials_9789264266414-6-en (visited on 04/12/2021).
- [3] Angela Y. Chang et al. “Past, Present, and Future of Global Health Financing: A Review of Development Assistance, Government, out-of-Pocket, and Other Private Spending on Health for 195 Countries, 1995–2050”. In: *The Lancet* 393.10187 (June 1, 2019), pp. 2233–2260. ISSN: 0140-6736, 1474-547X. DOI: 10.1016/S0140-6736(19)30841-4. pmid: 31030984. URL: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(19\)30841-4/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30841-4/abstract) (visited on 03/16/2021).
- [4] Tianqi Chen and Carlos Guestrin. “XGBoost: A Scalable Tree Boosting System”. In: *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* (Aug. 13, 2016), pp. 785–794. DOI: 10.1145/2939672.2939785. arXiv: 1603.02754. URL: <http://arxiv.org/abs/1603.02754> (visited on 03/19/2021).
- [5] Abigail R. Colson et al. “Quantifying Uncertainty about Future Antimicrobial Resistance: Comparing Structured Expert Judgment and Statistical Forecasting Methods”. In: *PLOS ONE* 14.7 (July 5, 2019), e0219190. ISSN: 1932-6203. DOI: 10.1371/journal.pone.0219190. URL: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219190> (visited on 03/11/2021).
- [6] European Centre for Disease Prevention and Control. *Antimicrobial Consumption Database (ESAC-Net)*. European Centre for Disease Prevention and Control. URL: <https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database> (visited on 04/15/2021).
- [7] European Centre for Disease Prevention and Control. *Antimicrobial Resistance*. Surveillance Atlas of Infectious Diseases. Mar. 19, 2021. URL: <https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4> (visited on 03/19/2021).
- [8] European Commission. *Eurostat*. URL: <https://ec.europa.eu/eurostat> (visited on 04/12/2021).
- [9] Eurostat. *Population on 1 January by Age and Sex*. Eurostat. Mar. 12, 2021. URL: https://ec.europa.eu/eurostat/databrowser/view/demo_pjan/default/table?lang=en (visited on 03/19/2021).
- [10] Eurostat. *Population on 1st January by Age, Sex and Type of Projection*. Eurostat. Feb. 8, 2021. URL: https://ec.europa.eu/eurostat/databrowser/view/proj_19np/default/table?lang=en (visited on 03/19/2021).
- [11] A. Galicia et al. “Multi-Step Forecasting for Big Data Time Series Based on Ensemble Learning”. In: *Knowledge-Based Systems* 163 (Jan. 1, 2019), pp. 830–841. ISSN: 0950-7051. DOI: 10.1016/j.knosys.2018.10.009. URL: <https://www.sciencedirect.com/science/article/pii/S0950705118304957> (visited on 03/19/2021).
- [12] Herman Goossens et al. “Outpatient Antibiotic Use in Europe and Association with Resistance: A Cross-National Database Study”. In: *The Lancet* 365.9459 (Feb. 12, 2005), pp. 579–587. ISSN: 0140-6736. DOI: 10.1016/S0140-6736(05)17907-0. URL: <https://www.sciencedirect.com/science/article/pii/S0140673605179070> (visited on 04/12/2021).
- [13] L Hakkaart-van Roijen et al. *Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg*. Diemen: Zorginstituut Nederland, 2015. URL: [https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+\(verdiepingsmodules\).pdf](https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+(verdiepingsmodules).pdf) (visited on 04/15/2021).

- [14] Tiago Cravo Oliveira Hashiguchi et al. “Resistance Proportions for Eight Priority Antibiotic-Bacterium Combinations in OECD, EU/EEA and G20 Countries 2000 to 2030: A Modelling Study”. In: *Euro-surveillance* 24.20 (May 16, 2019), p. 1800445. ISSN: 1560-7917. DOI: 10.2807/1560-7917.ES.2019.24.20.1800445. URL: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.20.1800445> (visited on 07/11/2019).
- [15] James Honaker, Gary King, and Matthew Blackwell. “Amelia II: A Program for Missing Data”. In: *Journal of Statistical Software* 45.1 (1 Dec. 12, 2011), pp. 1–47. ISSN: 1548-7660. DOI: 10.18637/jss.v045.i07. URL: <https://www.jstatsoft.org/index.php/jss/article/view/v045i07> (visited on 03/19/2021).
- [16] R.J. Hyndman and G Athanasopoulos. *Forecasting: Principles and Practice (3rd Ed)*. 3rd edition. Melbourne, Australia: OTexts, Mar. 17, 2021. URL: <https://Otexts.com/fpp3/> (visited on 03/19/2021).
- [17] M. Ieven et al. “Aetiology of Lower Respiratory Tract Infection in Adults in Primary Care: A Prospective Study in 11 European Countries”. In: *Clinical Microbiology and Infection* 24.11 (Nov. 1, 2018), pp. 1158–1163. ISSN: 1198-743X. DOI: 10.1016/j.cmi.2018.02.004. pmid: 29447989. URL: [https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(18\)30152-6/abstract](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(18)30152-6/abstract) (visited on 08/21/2020).
- [18] OECD. *Long-Term Baseline Projections, No. 103*. OECD, Aug. 2018. DOI: 10.1787/68465614-en. URL: https://www.oecd-ilibrary.org/economics/data/oecd-economic-outlook-statistics-and-projections/long-term-baseline-projections-no-103_68465614-en (visited on 03/19/2021).
- [19] Philipp Probst, Marvin Wright, and Anne-Laure Boulesteix. “Hyperparameters and Tuning Strategies for Random Forest”. In: *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery* 9.3 (May 2019). ISSN: 1942-4787, 1942-4795. DOI: 10.1002/widm.1301. arXiv: 1804.03515. URL: <http://arxiv.org/abs/1804.03515> (visited on 03/22/2021).
- [20] Claire Rothery et al. “Framework for Value Assessment of New Antimicrobials”. In: *Policy Research Unit in Economic Evaluations of Health & Care Interventions: New York, NY, USA* (2018).
- [21] The World Bank. *GDP per Capita, PPP (Constant 2017 International \$)*. The World Bank Data. URL: <https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.KD> (visited on 03/19/2021).
- [22] Alike W. van der Velden et al. “Primary Care for Patients with Respiratory Tract Infection before and Early on in the COVID-19 Pandemic: An Observational Study in 16 European Countries”. In: *BMJ Open* 11.7 (July 1, 2021), e049257. ISSN: 2044-6055, 2044-6055. DOI: 10.1136/bmjopen-2021-049257. pmid: 34326052. URL: <https://bmjopen.bmj.com/content/11/7/e049257> (visited on 11/03/2021).
- [23] Marvin N. Wright and Andreas Ziegler. “Ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R”. In: *Journal of Statistical Software* 77.1 (1 Mar. 31, 2017), pp. 1–17. ISSN: 1548-7660. DOI: 10.18637/jss.v077.i01. URL: <https://www.jstatsoft.org/index.php/jss/article/view/v077i01> (visited on 03/19/2021).
- [24] Zorginstituut Nederland. *Medicijnkosten*. Medicijnkosten. URL: <https://www.medicijnkosten.nl/> (visited on 04/15/2021).